Navigation Links
MIT Receives First ARRONAX Shipment, Launching Strontium-82 Validation Project

LUBBOCK, Texas, Feb. 21, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 16, 2012, MIT, received its first shipment of strontium-82(Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France. 

This historic event marks the first shipment of Sr-82 to be received by a private, non-government, entity in the U.S. in support of Sr-82 production. The receipt of this material also marks the beginning of MIT's validation efforts in order to qualify Sr-82 product material as Active Pharmaceutical Ingredient (API).

Over the next six months MIT will continue to obtain Sr-82 target solutions, from foreign irradiators at the facility in Lubbock, Texas.  MIT will conduct the critical processing procedures for final purification into API grade Sr-82.  Validation of the API grade Sr-82 product material is key to the Positron/MIT 2012 Drug Master File submission to the U.S. FDA.

"With the receipt of Sr-82 from ARRONAX, Positron and MIT have achieved an incredible milestone," states MIT President and Positron Pharmaceutical, Chief Technical Officer, Jason Kitten. "Up until this point in time, the Department of Energy was the only organization in the United States capable of processing Sr-82 material. By executing our plans, MIT is well positioned to meet the Drug Master File qualifications, which will further advance and accelerate Positron's Sr-82 mission. Positron continues its progress and is on schedule to meet 2012 Sr-82 supply objectives. Positron's goal of solidifying and advancing cardiac PET's progression in the U.S. is well underway."

About Positron:

Positron Corporation is a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at

Forward Looking Statements:

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

SOURCE Positron Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
2. The Apothecary Shops Receives Exclusive Distribution Rights for Mitosol®
3. Waltonen Engineering, Inc., Receives GSA Schedule
4. Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed
5. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
6. Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wifes Organs
7. Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
8. Large Orthopedic Practice Receives Vizteks Complete Orthopedic DR+PACS Bundle
9. Ocular Therapeutix, Inc. Receives IDE Approval to Conduct a Pivotal Clinical Trial for ReSure™ Sealant
10. United Therapeutics Receives Paragraph IV Notice Letter for Remodulin
11. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
Post Your Comments:
(Date:11/27/2015)... Nov. 26, 2015 ... of the "2016 Global Tumor Marker ... Volume and Sales Segment Forecasts, Innovative Technologies, ... report to their offering. --> ... the "2016 Global Tumor Marker Testing ...
(Date:11/26/2015)... WILMINGTON, North Carolina , 26 november ... Laboratories, Inc. (AAIPharma/CML) kondigt de geplande investering ... de uitbreiding van de laboratoria en het ... . De uitbreiding zal resulteren in ... waarmee wordt voldaan aan de groeiende behoeften ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock ... concert posters. This is one of Joplin's most famous and beautiful concert posters. The ... of Michigan in Ann Arbor. The According to Hawley, "It is hard to believe ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
Breaking Medicine News(10 mins):